|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Extracellular vesicle activities regulating macrophage- and tissue-mediated injury and repair responses显示文摘Macrophages are typically identified as classically activated(M1) macrophages and alternatively activated(M2) macrophages,which respectively exhibit pro-and anti-inflammatory phenotypes,and the balance between these two subtypes plays a critical role in the regulation of tissue inflammation,injury,and repair processes.Recent studies indicate that tissue cells and macrophages interact via the release of small extracellular vesicles(EVs) in processes where EVs released by stressed tissue cells can promote the activation and polarization of adjacent macrophages which can in turn release EVs and factors that can promote cell stress and tissue inflammation and injury and vice versa.This review discusses the roles of such EVs in resulating such interactions to influence tissue inflammation and injury in a number of acute and chronic inflammatory disease conditions,and the potential applications,advantage and concerns for using EV-based therapeutic approaches to treat such conditions,including their potential role of drug carriers for the treatment of infectious diseases. | Qian Hu Christopher J.Lyon Jesse K.Fletcher Wenfu Tang Meihua Wan Tony Y.Hu | 2021 | Acta Pharmaceutica Sinica B2021，11，6： | 22 |
| 2 | Strategies for advanced personalized tuberculosis diagnosis:Current technologies and clinical approaches显示文摘Diagnosis of tuberculosis can be difficult as advances in molecular diagnosis approaches(especially nanoparticles combined with high-throughput mass spectrometry for detecting mycobacteria peptide)and personalized medicine result in many changes to the diagnostic framework.This review will address issues concerning novel technologies from bench to bed and new strategies for personalized tuberculosis diagnosis. | Xuerong Chen Tony Y.Hu | 2021 | Precision Clinical Medicine2021，4，1： | 2 |
| 3 | Extracellular vesicles:Emerging tools as therapeutic agent carriers显示文摘Extracellular vesicles(EVs)are secreted by both eukaryotes and prokaryotes,and are present in all biological fluids of vertebrates,where they transfer DNA,RNA,proteins,lipids,and metabolites from donor to recipient cells in cell-to-cell communication.Some EV components can also indicate the type and biological status of their parent cells and serve as diagnostic targets for liquid biopsy.EVs can also natively carry or be modified to contain therapeutic agents(e.g.,nucleic acids,proteins,polysaccharides,and small molecules)by physical,chemical,or bioengineering strategies.Due to their excellent biocompatibility and stability,EVs are ideal nanocarriers for bioactive ingredients to induce signal transduction,immunoregulation,or other therapeutic effects,which can be targeted to specific cell types.Herein,we review EV classification,intercellular communication,isolation,and characterization strategies as they apply to EV therapeutics.This review focuses on recent advances in EV applications as therapeutic carriers from in vitro research towards in vivo animal models and early clinical applications,using representative examples in the fields of cancer chemotherapeutic drug,cancer vaccine,infectious disease vaccines,regenerative medicine and gene therapy.Finally,we discuss current challenges for EV therapeutics and their future development. | Shan Liu Xue Wu Sutapa Chandra Christopher Lyon Bo Ning Li jiang Jia Fan Tony Y.Hu | 2022 | Acta Pharmaceutica Sinica B2022，12，10： | 2 |
| 4 | Clinical Peptidomics: Advances in Instrumentation, Analyses, and Applications显示文摘Extensive effort has been devoted to the discovery,development,and validation of biomarkers for early disease diagnosis and prognosis as well as rapid evaluation of the response to therapeutic interventions.Genomic and transcriptomic profiling are well-established means to identify disease-associated biomarkers.However,analysis of disease-associated peptidomes can also identify novel peptide biomarkers or signatures that provide sensitive and specific diagnostic and prognostic information for specific malignant,chronic,and infectious diseases.Growing evidence also suggests that peptidomic changes in liquid biopsies may more effectively detect changes in disease pathophysiology than other molecular methods.Knowledge gained from peptide-based diagnostic,therapeutic,and imaging approaches has led to promising new theranostic applications that can increase their bioavailability in target tissues at reduced doses to decrease side effects and improve treatment responses.However,despite major advances,multiple factors can still affect the utility of peptidomic data.This review summarizes several remaining challenges that affect peptide biomarker discovery and their use as diagnostics,with a focus on technological advances that can improve the detection,identification,and monitoring of peptide biomarkers for personalized medicine. | Lin Li Jing Wu Christopher JLyon Li Jiang Tony Y.Hu | 2023 | Biomedical Engineering Frontiers2023，4，1： | 0 |
| 5 | Nanotechnology Powered CRISPR-Cas Systems for Point of Care Diagnosis and Therapeutic显示文摘Inspired by the successful application of Cas9 gene editing for“genome surgery,”we are looking back at what has been accomplished in the ten years of CRISPR editing.Intense effort is now focused on how to utilize the unique functions of CRISPR-Cas systems for molecular diagnostics and the next generation of therapeutic tools.CRISPR-Cas systems have two major advantages for gene editing that render them attractive for these new applications,specifically the ability to easily control their target recognition specificity and to couple this specificity to a targeted or secondary cleavage activity.However,despite the great potential of CRISPR/Cas for both gene editing and diagnosis,its medical applications have yet to be fully realized due factors that limit their delivery or utility for point-of-care(POC)applications.In this editorial note,we discuss how nanotechnology can address challenges associated with new CRISPR applications and what nanotechnology-specific advances are needed to circumvent remaining barriers that limit the development or use of new CRISPR/CAS-based genome editing and diagnostic approaches. | Chen-zhong Li Tony Y.Hu | 2023 | Research2023，，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员